Anbio Biotechnology NNNN
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -88.08%
- 1 year
- -70.83%
- Market cap
- 157.35M
- Revenue (ttm)
- 8.65M
- Profit margin
- 74.06%
- EPS (ttm)
- 0.15
- Shares out
- 43.89M
- P/E ratio
- 23.90
- YTD return
- -88.08%
- 1-year return
- -70.83%
- Volume
- 29.08K
- Avg volume
- 150.57K
- Open
- 3.50
- Previous close
- 3.51
- Day's range
- 3.50 – 3.75
- 52-week range
- 3.09 – 44.73
2Y -2.18 (-37.78%)
Key statistics
- Enterprise value
- 400.24M
- PEG ratio
- 0.00
- Price / sales
- 47.66
- Price / book
- 13.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 73.90%
- Free cash flow
- -9.61M
- Total cash
- 11.90M
- Total debt
- 0
- Return on equity
- 27.05%
- Short % of float
- 0.20%
- 50-day average
- 22.29
- 200-day average
- 25.98
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Anbio Biotechnology
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Germany
- Website
- anbiobiotechnology.com
News
Your note
Sign in to keep a note on NNNN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.06% | 25,763 | 241.91K | Mar 30, 2026 |
| BNP Paribas Financial Markets | 0.02% | 10,400 | 97.66K | Mar 30, 2026 |
| Morgan Stanley | 0.02% | 7,338 | 68.90K | Mar 30, 2026 |
| UBS Group AG | 0.01% | 6,339 | 59.52K | Mar 30, 2026 |
| Blue Trust, Inc. | 0.00% | 5 | 46 | Mar 30, 2026 |
| Wells Fargo & Company | 0.00% | 100 | 939 | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 26,736 | 251.05K | May 30, 2026 |